BioSpace News Archive

Ultivue, Inc. and, the Translational Research Unit platform of University of Bern announce a collaborative agreement to promote multiplexed immunofluorescence assays and the use of next generation TMAs to unlock spatial analysis in scientific research and improve the quality of TMAs integrated in clinical and translational research.

Cell coding company bit.bio has announced an expansion to its product portfolio - ioGlutamatergic Neurons TDP-43M337V disease model and early access to its ioMicroglia cell product.

NeuShen Therapeutics, Inc. announced the closure of ~$20 million Series pre-A financing led by LAPAM, a China based venture capital.

Galecto, Inc. announced positive results from a planned intermediate assessment of its ongoing Phase 2a trial of GB2064 for the treatment of myelofibrosis.

Spectrum Chemical Mfg. Corp. has entered into a new U.S. distribution agreement with DFE Pharma, a global leader in pharma and nutraceutical excipient solutions.

Axcella Therapeutics reported interim results from their ongoing global Phase 2b randomized, double-blind, placebo-controlled, dose ranging EMMPACT study to evaluate the safety, tolerability, and efficacy of AXA1125 for the treatment of NASH.

MolecuLight Corp. announces it has been awarded a new group purchasing agreement with AllSpire Health GPO, a Mid-Atlantic GPO and a partner of HealthTrust Purchasing Group, engaged with over fifty hospitals in Maryland, New Jersey and Pennsylvania.

Caris Life Sciences®, the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize health care, announced that St. Luke’s University Health Network has joined Caris’ Precision Oncology Alliance™.

Merck, known as MSD outside the United States and Canada, will hold its third-quarter 2022 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. ET on Thursday, October 27.

BD, a leading global medical technology company, in conjunction with Heart to Heart International, the National Association of Free and Charitable Clinics and Henry Schein Cares, announced that six U.S. free and charitable clinics will be awarded product-based grants worth a total of $360,000 to support point-of-care diagnostic testing in communities with underserved and at-risk patient populations.